Scholarlink

Background <p>Dexamethasone has been used extensively to prevent hypersensitivity reactions to paclitaxel. However, the optimal dose of dexamethasone is controversial, varying between 20&#xa0;mg and 10&#xa0;mg. We conducted this randomized controlled trial to illustrate that these 2 dosages of dexamethasone are non-inferior to the prevention of paclitaxel HSRs.</p> Methods <p>Gynecologic cancer patients who naively receive paclitaxel and carboplatin were invited to participate in this study. All participants received the same premedication with intravenous dexamethasone 20&#xa0;mg, oral lorazepam 0.5&#xa0;mg, and intravenous chlorpheniramine 10&#xa0;mg at the first cycle. If they did not develop hypersensitivity reactions, they were randomized to receive either intravenous 20&#xa0;mg or 10&#xa0;mg dexamethasone with the same other premedication. The attending nurse recorded the patient’s symptoms regarding hypersensitivity reactions. The main outcome was hypersensitivity reaction events in each arm, with a non-inferiority margin of 0.11.</p> Results <p>A total of 122 patients were included and randomly assigned to receive dexamethasone 10&#xa0;mg (<i>n</i> = 61) or dexamethasone 20&#xa0;mg (<i>n</i> = 61). The overall incidence of hypersensitivity reactions in patients who received dexamethasone 10&#xa0;mg and dexamethasone 20&#xa0;mg was 9.8% and 13.1%, respectively, the risk difference between dexamethasone 10&#xa0;mg and dexamethasone 20&#xa0;mg not exceeding the non-inferiority margin of 0.11 (Risk Difference = -0.03, 95% confidence interval = -0.15 to 0.08).</p> Conclusion <p>Dexamethasone 10&#xa0;mg was non-inferior to dexamethasone 20&#xa0;mg in terms of prevention of paclitaxel hypersensitivity reactions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy of premedication with 10 mg versus 20 mg of intravenous dexamethasone for prevention of paclitaxel hypersensitivity reaction in low-risk gynecologic cancer patients: a non-inferiority, randomized controlled mono-institutional trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月16日

查看全文
  • Nutthakarn Sa-ngiamphorn,
  • Prapaporn Suprasert,
  • Chaiyut Charoentum

摘要

Background

Dexamethasone has been used extensively to prevent hypersensitivity reactions to paclitaxel. However, the optimal dose of dexamethasone is controversial, varying between 20 mg and 10 mg. We conducted this randomized controlled trial to illustrate that these 2 dosages of dexamethasone are non-inferior to the prevention of paclitaxel HSRs.

Methods

Gynecologic cancer patients who naively receive paclitaxel and carboplatin were invited to participate in this study. All participants received the same premedication with intravenous dexamethasone 20 mg, oral lorazepam 0.5 mg, and intravenous chlorpheniramine 10 mg at the first cycle. If they did not develop hypersensitivity reactions, they were randomized to receive either intravenous 20 mg or 10 mg dexamethasone with the same other premedication. The attending nurse recorded the patient’s symptoms regarding hypersensitivity reactions. The main outcome was hypersensitivity reaction events in each arm, with a non-inferiority margin of 0.11.

Results

A total of 122 patients were included and randomly assigned to receive dexamethasone 10 mg (n = 61) or dexamethasone 20 mg (n = 61). The overall incidence of hypersensitivity reactions in patients who received dexamethasone 10 mg and dexamethasone 20 mg was 9.8% and 13.1%, respectively, the risk difference between dexamethasone 10 mg and dexamethasone 20 mg not exceeding the non-inferiority margin of 0.11 (Risk Difference = -0.03, 95% confidence interval = -0.15 to 0.08).

Conclusion

Dexamethasone 10 mg was non-inferior to dexamethasone 20 mg in terms of prevention of paclitaxel hypersensitivity reactions.